NervGen Pharma Corp. NGEN
—
1.94
(0.08)
(3.96%)
as of 25 Sep
- Market cap
- $217.2M
- P/E
- 0.0×
Follow NGEN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (754.40%) | (1,200.23%) | (1,445.60%) | — |
+3 more TTM periods Free account |
|
| (115.19%) | (229.66%) | (204.82%) | — | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(365.19%) | (801.01%) | (1,438.09%) | 0.00% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.20) | (0.21) | (0.19) | (0.30) | |
Free Cash Flow |
(18.39) | (17.06) | (13.96) | (21.80) | |
Piotroski F-Score |
1.00 | 1.00 | 1.00 | — | |
| Other line items | |||||
Cash ROIC |
(24.47%) | (105.93%) | (76.30%) | (355.20%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | — | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | — | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | — | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | — | |
Interest Coverage |
0.00 | 0.00 | 0.00 | — | |
Operating CF/Net income |
0.41 | 0.57 | 0.44 | 0.00 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.20) | (0.21) | (0.19) | (0.30) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | — |
Columns are period end dates